

Dispense as written/Brand medically necessary

Referral Status:	MRN:	
New referral	Order change	Order Renewal
Patient preferred clinic:		

Substitution permitted

Pho	Phone: 1-800-809-1265 Fax: 1-866-872-8920									
Ste	elara® (ustekinumab) Plant of T	reatment for	Rhe	umatology	& Dermatology	V				
	TIENT DEMOGRAPHICS:			87	8					
Date of Referral:			Patient's Phone:							
Patient Name:			Address:							
Date of Birth:			City, State, Zip:							
Heig	ht in inches: Weight: LB	or KG	Gend	er:	Allergies:	Se	ee list	NDKA		
		-RD								
DIA	GNOSIS: (PLEASE COMPLETE 2 ND AND	B" DIGITS TO COI	MPLE							
	L40.50 - Arthropathic psoriasis, unspecified			L40.0 - Psoriasis v						
	L40.59 - Other psoriatic arthropathy - Other:			L40.9 - Psoriasis,	unspecined					
DEC		DDEVIOUS ADMINI	CTD A	TION: HAC THIS	DATIENT TAKEN TILL	NAFRICATI	ON REE	ODE3		
	QUESTED DOCUMENTATION:	IF NO:			PATIENT TAKEN THIS	MEDICATI	ON BEF	OKE?		
1 2	Insurance information Most recent History & Physical	PLEASE STATE		IF YES: LAST INJECTION DATE: NEXT INJECTION DATE:						
3	Full medication list	REQUIRED WASHOUT								
4	Tried and failed therapies	FROM PREVIOUS THERAPY:		DER CHANGE:	- .					
5	REQUIRED: TB screening for new start patients	IIILIVAFI.	0.	LER GHARGE.						
6				Continue	current order until	ent order until insurance approved				
ME	DICATION ORDERS:									
	E: Patient may be ineligible to receive ustekinumab if rece	iving antibiotics for active	infectio	us process, antifungal	therapy, active fever and/or	suspected inf	ection, new	w-onset or		
	ioration neurological changes, and/or surgery									
DO	SE/FREQUENCY:									
	Stelara [®] (ustekinumab) 45mg subcutar	•			40					
		tion at 0 week, 4 w		-	12 weeks					
	<u> Maintenance:</u> ir	njection every 12 w	eeks							
	Stelara [®] (ustekinumab) 90mg subcutar	eous injection								
	Induction: Inject	tion at 0 week, 4 w	eek,	and then every	12 weeks					
	Maintenance: Ir	njection every 12 w	eeks/							
*N	ote: 90mg dose only suggested for patients gr	eater than 100kg with	n psor	iasis or psoriatic	arthritis with co-existe	nt moderate	to seve	re plaque		
		ps	oriasi	s.						
	Administer as a subcutaneous injection to the upper arm, gluteal region, thigh, or abdomen									
SPE	CIAL ORDERS:									
	1									
			V	Refills x 12 months unless noted otherwise here:						
LIN	E USE/CARE ORDERS:		ADVERSE REACTION & ANAPHYLAXIS ORDERS:							
	Start PIV/Access CVC		Administer acute infusion and anaphylaxis							
Flush device per facility standard flushing procedure				medications per Palmetto Infusion standing						
	Flush device per lacility standard hushing p	nocedure		adverse reaction orders, which can be found at our						
				website or scan he	ere.		(1337) (1337)			
							■ .₩	2000年		
PRE	SCRIBER INFORMATION:									
PROVIDER NAME:				PHONE:						
ADDRESS:				FAX:						
CITY, STATE, ZIP:				NPI:						
PRE	SCRIBER SIGNATURE: (No stamp signa	tures)				DATI	Ē			